Peter F. Thall

The University of Texas MD Anderson Cancer Center

MathematicsMedicineDecision SciencesEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 24 papers. Top paper: “Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors”.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

New England Journal of Medicine(2020)10.1056/nejmoa1910607

N/A

5.4DataRank · unranked

2164 citations

David Marín, Pinaki P. Banerjee, Homer A. Macapinlac, Philip A. Thompson, Rafet Başar +22 more

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

Nature Medicine(2024)10.1038/s41591-023-02785-8

N/A

4.0DataRank · unranked

468 citations

Ye Li, Rafet Başar, Hind Rafei, May Daher, Jinzhuang Dou +31 more

Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

Journal of Clinical Oncology(2021)10.1200/jco.20.02608

N/A

2.1DataRank · unranked

66 citations

Ruitao Lin, David Marín, Hind Rafei, Mustafa Bdiwi, Peter F. Thall +38 more

Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial

The Lancet Oncology(2023)10.1016/s1470-2045(23)00478-3

N/A

0.960DataRank · unranked

34 citations

Jessica M. Frakes, Todd A. Aguilera, Manisha Palta, Brian G. Czito, Manoop S. Bhutani +26 more

A Causal Framework for Making Individualized Treatment Decisions in Oncology

Cancers(2022)10.3390/cancers14163923

N/A

0DataRank · unranked

37 citations

Juhee Lee, José A. Karam, Peter F. Thall, Pavlos Msaouel

A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Adults

Practical Radiation Oncology(2022)10.1016/j.prro.2022.12.006

N/A

0DataRank · unranked

9 citations

Dershan Luo, Jason M. Johnson, Kham Nguyen, Jing Li, Mary Frances McAleer +10 more

A Bayesian piecewise exponential phase II design for monitoring a time‐to‐event endpoint

Pharmaceutical Statistics(2022)10.1002/pst.2256

N/A

0DataRank · unranked

5 citations

Peter F. Thall, Ying Yuan, Yun Qing

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation

Bone Marrow Transplantation(2022)10.1038/s41409-022-01705-7

N/A

0DataRank · unranked

10 citations

Peter F. Thall, Junsheng Ma, Benigno C. Valdez, Roland L. Bassett, Julianne Chen +20 more

Generalized phase I‐II designs to increase long term therapeutic success rate

Pharmaceutical Statistics(2023)10.1002/pst.2301

N/A

0DataRank · unranked

12 citations

Yong Zang, Ying Yuan, Peter F. Thall

Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2222

N/A

0DataRank · unranked

8 citations

Yong Zang, Andrew Chapple, Ying Yuan, Ruitao Lin, David Marín +2 more

Risk–benefit trade-offs and precision utilities in phase I-II clinical trials

Clinical Trials(2023)10.1177/17407745231214750

N/A

0DataRank · unranked

3 citations

Juhee Lee, Peter F. Thall, Pavlos Msaouel

Interpreting Randomized Controlled Trials

Preprints.org(2023)10.20944/preprints202309.0093.v1

N/A

0DataRank · unranked

2 citations

Juhee Lee, Peter F. Thall, Pavlos Msaouel

A Bayesian feature allocation model for identifying cell subpopulations using CyTOF data

Journal of the Royal Statistical Society Series C (Applied Statistics)(2023)10.1093/jrsssc/qlad029

N/A

0DataRank · unranked

0 citations

Juhee Lee, Peter F. Thall, May Daher, Katy Rezvani, Rafet Başar +1 more

Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus

Clinical Trials(2024)10.1177/17407745241234652

N/A

0DataRank · unranked

8 citations

Elizabeth Garrett‐Mayer, Nolan A. Wages, Susan Halabi, Ying Kuen Cheung, Peter F. Thall

ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications

Biometrics(2024)10.1093/biomtc/ujae105

N/A

0DataRank · unranked

4 citations

Peter F. Thall, Kentaro Takeda, Ying Yuan, Shuqi Wang

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.10.022

N/A

0DataRank · unranked

5 citations

Salvatore La Rosa, Tian Zhang, Phillip M. Pierorazio, Laurence Albigès, Kathryn E. Beckermann +19 more

Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility‐Based Rule

Statistics in Medicine(2024)10.1002/sim.10254

N/A

0DataRank · unranked

4 citations

Peter F. Thall, Juhee Lee

Intraoperative methadone administration for total mastectomy: A single center retrospective study

Journal of Clinical Anesthesia(2024)10.1016/j.jclinane.2024.111572

N/A

0DataRank · unranked

5 citations

Yusuf Zaidi, Juan Jose Guerra-Londoño, Evan D. Kharasch, Matthew Piotrowski, Spencer Kee +5 more

A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison

Biometrics(2024)10.1093/biomtc/ujad022

N/A

0DataRank · unranked

3 citations

Peter F. Thall, Ying Yuan, Yong Zang

High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1917

N/A

0DataRank · unranked

2 citations

John F. Ward, Wayne L. Hofstetter, David C. Rice, José A. Karam, Louis L. Pisters +24 more

Precision generalized phase I-II designs

Biometrics(2025)10.1093/biomtc/ujaf043

N/A

0DataRank · unranked

0 citations

Peter F. Thall, Ying Yuan, Juhee Lee, Pavlos Msaouel, Yong Zang +1 more

A Phase I–II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes

Bayesian Analysis(2020)10.1214/20-ba1205

N/A

0DataRank · unranked

17 citations

Peter F. Thall, Ying Yuan, Ruitao Lin

Robust Adaptive Incorporation of Historical Control Data in a Randomized Trial of External Cooling to Treat Septic Shock

Bayesian Analysis(2020)10.1214/20-ba1229

N/A

0DataRank · unranked

6 citations

Peter F. Thall, Frédérique Schortgen, Pierre Asfar, Sarah Zohar, Sandrine Katsahian +1 more

Phase 1 study of spinal cord constraint relaxation with single session spine stereotactic radiosurgery in the primary management of patients with inoperable, previously irradiated metastatic epidural spinal cord compression

North American Spine Society Journal (NASSJ)(2021)10.1016/j.xnsj.2021.100066

N/A

0DataRank · unranked

6 citations

Nandita Guha‐Thakurta, Juhee Song, Peter F. Thall, Tina M. Briere, Stephen H. Settle +8 more